Skip to main content
Signal8

REPLIGEN CORP (RGEN)

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Medical - Instruments & Supplies

Repligen Corporation logo

Repligen Corporation

NASDAQ:RGENHealthcare
-6.20%$176.94
AH$176.94+0.00%vs close
Mkt Cap$11.31B
Float55.96M
O/S63.92M
Vol
$ Vol
RVOL
Inst Own-
SI12.8%
Earnings
Dilution
Phase Distribution
6 lead-sponsored trials·0 active·4 completed
Phase 11
Phase 22
Phase 33
(4 more as collaborator)
Status Overview
Completed4
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction

    RG1068 (Synthetic Human Secretin)

    Autism

    Enrollment
    -
    Start
    Apr 2002
    Primary Completion
    -
    Completion
    -
    NCT00036231
  • Phase 3
    Completed

    Synthetic Human Secretin in Children With Autism

    RG1068 (Synthetic Human Secretin)

    Autism

    Enrollment
    -
    Start
    Apr 2002
    Primary Completion
    -
    Completion
    Jan 2004
    NCT00036244
  • Phase 3
    Completed

    Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas

    RG1068 (synthetic human secretin)

    Pancreatitis

    Enrollment
    258
    Start
    Mar 2008
    Primary Completion
    Oct 2009
    Completion
    Oct 2009
    NCT00660335
  • Phase 2
    Completed

    Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

    Uridine

    Bipolar Depression

    Enrollment
    80
    Start
    Mar 2006
    Primary Completion
    -
    Completion
    -
    NCT00322764
  • Phase 2
    Completed

    A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

    RG2417, Placebo

    Bipolar I Depression

    Enrollment
    180
    Start
    Nov 2008
    Primary Completion
    Dec 2010
    Completion
    Dec 2010
    NCT00812058
  • Phase 1
    Terminated

    RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

    RG2133 (2',3',5'-tri-O-acetyluridine)

    Mitochondrial Diseases

    Enrollment
    12
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT00060515